The 96wks. trial results evaluating aflibercept (8mg, 12 & 16wk. dosing regimens) vs 8wk. dosing regimen for Eylea in 1009 patients
The trial met its 1EPs i.e., 88% were on a ≥12wk. dosing interval at the end of 2yrs., 78% maintained ≥12wk. dosing intervals throughout 2yr. study over 83% in 1yr. of study (48wks.), 71% met extension criteria for even longer dosing intervals incl. 47% for ≥20wk. intervals & 28% for 24wk. intervals, 70% maintained ≥16wk. dosing intervals throughout 2yr. study period; 78% & 53% were eligible for ≥16 & ≥20-dosing wk. intervals
The safety continued to be similar to Eylea through 2yrs. & remained consistent with the known safety profile of Eylea from prior trials, vision gains were sustained, the rate of intraocular inflammation (1.3% vs 2.1%), arterial thromboembolic TEAEs (1.8% vs 3.3%)
Ref: Globenewswire | Image: Regeneron
Related News:- Regeneron Presented Two-Year Results from (PHOTON) Trial of Aflibercept for Diabetic Macular Edema at ASRS 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
